Olivia Vizier

On Wednesday, BeyondSpring, a small New York biotech with an offbeat approach to immunotherapy, announced its lead drug significantly extended non-small cell lung cancer patients’ lives in a large trial. Although the company did not release the exact survival data, it said that nearly twice as many patients were alive after two years on the […]

Dale Christensen, with Austin-based drug developer TFF Pharmaceuticals, says they’ve got an easy solution to getting a monoclonal antibody treatment straight to your doorstep — rather than being hooked up to a machine and IV.

The cure for this new threat may rest with Cidara Therapeutics’ new antifungal drug, rezafungin. It currently is completing two Phase III trials. One treats candidemia and invasive candidiasis. On the other, rezafungin is used as a prophylactic for the prevention of fungal infections in a high-risk hematology setting. It shows efficacy against Candida spp., Aspergillus spp., Pneumocystis spp. and dermatophytes,

“Renovacor is in a similar situation to the one MyoKardia was in five years ago,” says Dr. Semigran. “We have knowledge of the mechanism of action of dilated cardiomyopathy, where there’s an inadequate amount of a required protein for the heart muscle to function correctly. And fortunately, I think the field of selective gene therapy

The therapy was developed by Jersey City, New Jersey-based biotechnology company, Scynexis. The company has also been studying ibrexafungerp in its CARES study in hospitalized patients with C. auris.

“When big pharma collaborates with biopharma companies, the main risk isn’t the technology, but the commitment of the partner,” according to serial entrepreneur Yochi Slonim, CEO of Anima Biotech. That isn’t merely his opinion. The question arises in partnering meetings routinely.

Swiss pharma company Araris Biotech AG is attracting attention based on ongoing research with its linker technology for antibody drug conjugate delivery. The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.

Heat Biologics, still have the potential to play a big role in ending the pandemic.

Sio Gene Therapies is pushing the boundaries of gene therapy to develop treatments for three debilitating neurodegenerative diseases, including clinical-stage product candidates in rare fatal pediatric disorders and adult Parkinson’s disease.

Ikena Oncology changed its name in late 2019 after a three-month deliberation process; the company previously went by Kyn Therapeutics. 

Craig Fraser, CEO of Windtree Therapeutics, became a U.S. Marine at age 17, learning to perform and lead under pressure in the field before eventually leading in the C-suite.

OncoSec Medical’s Tavo, a DNA-based interleukin-12 immunotherapy that is delivered to tumors via electroporation, is currently in Phase II trials

Scynexis announced it will commercially launch its Brexafemme (ibrexafungerp) therapy in the 3rd quarter of 2021 at a media event today. The company plans a full marketing rollout for its launch in the coming months.

OncoSec’s DNA-delivery system is designed to prompt the body to make more of its own IL-12. “The DNA essentially co-opts the cell’s function to cause it to make IL-12,” explained Daniel O’Connor, former CEO of OncoSec, in an interview.

A so-called multivalent vaccine might protect against all Covid-19 mutations and any future pathogen from the betacoronavirus family

Augmenta Bioworks and TFF Pharmaceuticals Inc have selected their first lead monoclonal antibody (mAb) for clinical development against COVID-19 as part of their collaborative alliance.

Following a collaboration agreement in November 2020, Augmenta Bioworks and TFF Pharmaceuticals have selected AUG-3387 as their lead candidate in COVID-19.

The clinical-stage biopharma unveiled the $74 million series B financing Wednesday, brought in from new investors Slate Path Capital, Palkon Capital, ArrowMark Partners and 683 Capital on top of existing backers like Sporos Bioventures.

Arrowhead Pharmaceuticals has added to its collection of RNA collaborations with a $40 million upfront deal with Horizon Therapeutics.

You might expect to find Dr. Robert Hariri strolling through the headquarters of Celularity, the biotechnology company he founded, outfitted in PPE and sterile paper slippers. But when we caught up with this 62-year-old, physically fit aviator, he was in his light-filled office in the 150,000-square-foot Florham Park, New Jersey facility, wearing a black shirt, black pants, and black boots.

The furthest along is a vaccine candidate co-developed by Pfizer, the U.S.-based pharmaceutical giant, and Valneva SE, a French biotech company. In March, the companies kicked off a Phase 2 trial in 600 people ages 5-65. The vaccine, which would be given in two to three doses, is very similar to LYMErix, but it targets six strains of Lyme

At Fore Biotherapeutics, we are leveraging our functional genomics platform, Foresight, to match populations of patients with rare cancer mutations to targeted therapies that have a high probability of making a difference. Our mission is to provide patients with unaddressed cancer mutations with rapid access to the right medicines.

The BeyondSpring Pharmaceuticals CEO Dr. Lan Huang talks through receiving U.S. FDA and China NMPA acceptance of its new drug application with priority review for use of its lead product Plinabulin. Huang says early clinical data supports Plinabulin as a direct anti-cancer agent in combination with PD1/PDL1 inhibitors in small cell lung cancer.